The role of protein kinase A in anaerobic energy production during liver storage

Thomas A. Churchill, Beatrice M. Wu, David F. Mercer, Norman M. Kneteman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aim: During cold liver storage in University of Wisconsin solution, glycolysis is inhibited by declining intracellular pH and a reduction in glycogen phosphorylase activity. The current study investigated the effects of a histidine-buffered, modified University of Wisconsin solution with cyclic-AMP analogue plus phosphodiesterase inhibitors to optimize both pH and PK A-mediated limits on glycolytic energy production. Methods: In an isolated rodent-liver system, dioctanoyl-cAMP was supplemented with each phosphodiesterase inhibitor (isobutylmethylxanthine, papaverine, Ro 20-1724, dipyridamole). Once the most efficacious combination was determined, a separate group of livers was cold-stored for 24 h and then reperfused at 37°C to examine regeneration of high energy adenylates. Results: Lactate accumulation in the histidine-lactobionate-raffinose group was 8.7 μmol/g; net increases were greater with all four phosphodiesterase inhibitors with dioctanoyl-cAMP; dipyridamole resulted in a maximum increase of 16.7 μmol/g. ATP was consistently higher in all treatment groups with phosphodiesterase inhibitors throughout 24 h; even after 10-24 h, levels with dipyridamole- treatment were 250-280% higher than with University of Wisconsin (p<0.05). Assessment of glycogen phosphorylase activity in the dipyridamole-treatment group indicated that increased glycolytic activity over the first 4 h was a direct consequence of elevated enzyme levels. However, between 410 h, phosphofructokinase underwent a phosphorylation, leading to an inhibition at this point in glycolysis. Upon reperfusion, the higher ATP/ADP and ADP/AMP ratios found with phosphodiesterase inhibitor treatment suggested that adenylate regeneration was superior with dipyridamole+dioctanoyl-cAMP. Conclusion: Dipyridamole plus dioctanoyl-cAMP treatment achieved increased glycogenolysis throughout 24 h storage by maintaining glycogen phosphorylase in a phosphorylated (active) state; however, a PK A-mediated phosphorylation (inhibition) of phosphofructokinase resulted in decreased glycolytic ATP production between 4-10 h.

Original languageEnglish (US)
Pages (from-to)473-480
Number of pages8
JournalJournal of Hepatology
Volume32
Issue number3
DOIs
StatePublished - Mar 2000

Fingerprint

Dipyridamole
Cyclic AMP-Dependent Protein Kinases
Phosphodiesterase Inhibitors
Glycogen Phosphorylase
Liver
Phosphofructokinases
Adenosine Triphosphate
Glycolysis
Histidine
Adenosine Diphosphate
Regeneration
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
Phosphorylation
Raffinose
Glycogenolysis
Papaverine
Adenosine Monophosphate
Cyclic AMP
Reperfusion
Rodentia

Keywords

  • Cyclic-AMP
  • Glycolysis
  • Hepatic energetics
  • Liver preservation
  • Phosphodiesterase inhibitors
  • Protein kinase A

ASJC Scopus subject areas

  • Hepatology

Cite this

The role of protein kinase A in anaerobic energy production during liver storage. / Churchill, Thomas A.; Wu, Beatrice M.; Mercer, David F.; Kneteman, Norman M.

In: Journal of Hepatology, Vol. 32, No. 3, 03.2000, p. 473-480.

Research output: Contribution to journalArticle

Churchill, Thomas A. ; Wu, Beatrice M. ; Mercer, David F. ; Kneteman, Norman M. / The role of protein kinase A in anaerobic energy production during liver storage. In: Journal of Hepatology. 2000 ; Vol. 32, No. 3. pp. 473-480.
@article{be5a53f5cbc6448395f49897d49507d1,
title = "The role of protein kinase A in anaerobic energy production during liver storage",
abstract = "Background/Aim: During cold liver storage in University of Wisconsin solution, glycolysis is inhibited by declining intracellular pH and a reduction in glycogen phosphorylase activity. The current study investigated the effects of a histidine-buffered, modified University of Wisconsin solution with cyclic-AMP analogue plus phosphodiesterase inhibitors to optimize both pH and PK A-mediated limits on glycolytic energy production. Methods: In an isolated rodent-liver system, dioctanoyl-cAMP was supplemented with each phosphodiesterase inhibitor (isobutylmethylxanthine, papaverine, Ro 20-1724, dipyridamole). Once the most efficacious combination was determined, a separate group of livers was cold-stored for 24 h and then reperfused at 37°C to examine regeneration of high energy adenylates. Results: Lactate accumulation in the histidine-lactobionate-raffinose group was 8.7 μmol/g; net increases were greater with all four phosphodiesterase inhibitors with dioctanoyl-cAMP; dipyridamole resulted in a maximum increase of 16.7 μmol/g. ATP was consistently higher in all treatment groups with phosphodiesterase inhibitors throughout 24 h; even after 10-24 h, levels with dipyridamole- treatment were 250-280{\%} higher than with University of Wisconsin (p<0.05). Assessment of glycogen phosphorylase activity in the dipyridamole-treatment group indicated that increased glycolytic activity over the first 4 h was a direct consequence of elevated enzyme levels. However, between 410 h, phosphofructokinase underwent a phosphorylation, leading to an inhibition at this point in glycolysis. Upon reperfusion, the higher ATP/ADP and ADP/AMP ratios found with phosphodiesterase inhibitor treatment suggested that adenylate regeneration was superior with dipyridamole+dioctanoyl-cAMP. Conclusion: Dipyridamole plus dioctanoyl-cAMP treatment achieved increased glycogenolysis throughout 24 h storage by maintaining glycogen phosphorylase in a phosphorylated (active) state; however, a PK A-mediated phosphorylation (inhibition) of phosphofructokinase resulted in decreased glycolytic ATP production between 4-10 h.",
keywords = "Cyclic-AMP, Glycolysis, Hepatic energetics, Liver preservation, Phosphodiesterase inhibitors, Protein kinase A",
author = "Churchill, {Thomas A.} and Wu, {Beatrice M.} and Mercer, {David F.} and Kneteman, {Norman M.}",
year = "2000",
month = "3",
doi = "10.1016/S0168-8278(00)80399-2",
language = "English (US)",
volume = "32",
pages = "473--480",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The role of protein kinase A in anaerobic energy production during liver storage

AU - Churchill, Thomas A.

AU - Wu, Beatrice M.

AU - Mercer, David F.

AU - Kneteman, Norman M.

PY - 2000/3

Y1 - 2000/3

N2 - Background/Aim: During cold liver storage in University of Wisconsin solution, glycolysis is inhibited by declining intracellular pH and a reduction in glycogen phosphorylase activity. The current study investigated the effects of a histidine-buffered, modified University of Wisconsin solution with cyclic-AMP analogue plus phosphodiesterase inhibitors to optimize both pH and PK A-mediated limits on glycolytic energy production. Methods: In an isolated rodent-liver system, dioctanoyl-cAMP was supplemented with each phosphodiesterase inhibitor (isobutylmethylxanthine, papaverine, Ro 20-1724, dipyridamole). Once the most efficacious combination was determined, a separate group of livers was cold-stored for 24 h and then reperfused at 37°C to examine regeneration of high energy adenylates. Results: Lactate accumulation in the histidine-lactobionate-raffinose group was 8.7 μmol/g; net increases were greater with all four phosphodiesterase inhibitors with dioctanoyl-cAMP; dipyridamole resulted in a maximum increase of 16.7 μmol/g. ATP was consistently higher in all treatment groups with phosphodiesterase inhibitors throughout 24 h; even after 10-24 h, levels with dipyridamole- treatment were 250-280% higher than with University of Wisconsin (p<0.05). Assessment of glycogen phosphorylase activity in the dipyridamole-treatment group indicated that increased glycolytic activity over the first 4 h was a direct consequence of elevated enzyme levels. However, between 410 h, phosphofructokinase underwent a phosphorylation, leading to an inhibition at this point in glycolysis. Upon reperfusion, the higher ATP/ADP and ADP/AMP ratios found with phosphodiesterase inhibitor treatment suggested that adenylate regeneration was superior with dipyridamole+dioctanoyl-cAMP. Conclusion: Dipyridamole plus dioctanoyl-cAMP treatment achieved increased glycogenolysis throughout 24 h storage by maintaining glycogen phosphorylase in a phosphorylated (active) state; however, a PK A-mediated phosphorylation (inhibition) of phosphofructokinase resulted in decreased glycolytic ATP production between 4-10 h.

AB - Background/Aim: During cold liver storage in University of Wisconsin solution, glycolysis is inhibited by declining intracellular pH and a reduction in glycogen phosphorylase activity. The current study investigated the effects of a histidine-buffered, modified University of Wisconsin solution with cyclic-AMP analogue plus phosphodiesterase inhibitors to optimize both pH and PK A-mediated limits on glycolytic energy production. Methods: In an isolated rodent-liver system, dioctanoyl-cAMP was supplemented with each phosphodiesterase inhibitor (isobutylmethylxanthine, papaverine, Ro 20-1724, dipyridamole). Once the most efficacious combination was determined, a separate group of livers was cold-stored for 24 h and then reperfused at 37°C to examine regeneration of high energy adenylates. Results: Lactate accumulation in the histidine-lactobionate-raffinose group was 8.7 μmol/g; net increases were greater with all four phosphodiesterase inhibitors with dioctanoyl-cAMP; dipyridamole resulted in a maximum increase of 16.7 μmol/g. ATP was consistently higher in all treatment groups with phosphodiesterase inhibitors throughout 24 h; even after 10-24 h, levels with dipyridamole- treatment were 250-280% higher than with University of Wisconsin (p<0.05). Assessment of glycogen phosphorylase activity in the dipyridamole-treatment group indicated that increased glycolytic activity over the first 4 h was a direct consequence of elevated enzyme levels. However, between 410 h, phosphofructokinase underwent a phosphorylation, leading to an inhibition at this point in glycolysis. Upon reperfusion, the higher ATP/ADP and ADP/AMP ratios found with phosphodiesterase inhibitor treatment suggested that adenylate regeneration was superior with dipyridamole+dioctanoyl-cAMP. Conclusion: Dipyridamole plus dioctanoyl-cAMP treatment achieved increased glycogenolysis throughout 24 h storage by maintaining glycogen phosphorylase in a phosphorylated (active) state; however, a PK A-mediated phosphorylation (inhibition) of phosphofructokinase resulted in decreased glycolytic ATP production between 4-10 h.

KW - Cyclic-AMP

KW - Glycolysis

KW - Hepatic energetics

KW - Liver preservation

KW - Phosphodiesterase inhibitors

KW - Protein kinase A

UR - http://www.scopus.com/inward/record.url?scp=0034010470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034010470&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(00)80399-2

DO - 10.1016/S0168-8278(00)80399-2

M3 - Article

C2 - 10735618

AN - SCOPUS:0034010470

VL - 32

SP - 473

EP - 480

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -